MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jcin.2026.07.009

Медицинская библиотека · JACC. Cardiovascular interventions · 2026

Redo-Transcatheter Aortic Valve Replacement With Self-Expanding Valves: A U.S. Registry Analysis.

Rogers Toby, Bapat Vinayak N, Chetcuti Stanley J, Dauerman Harold L, Forrest John K, Goel Sachin S, Grubb Kendra J, Htun Wah Wah, Puri Rishi, Reardon Michael J, Tang Gilbert H L, Vora Amit N, Yakubov Steven J, Eisenberg Ruth, Attizzani Guilherme F

Сравнительное исследованиеСтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Redo-transcatheter aortic valve replacement (TAVR) for failed transcatheter heart valves is expected to increase, but data on outcomes with self-expanding valves remain limited.

OBJECTIVES

The aims of this study were to evaluate procedural, clinical, and quality-of-life outcomes following redo-TAVR using self-expanding Evolut valves and to compare these outcomes with those among a contemporary native TAVR cohort.

METHODS

Outcomes after redo-TAVR with Evolut R, Evolut PRO, and Evolut PRO+ valves in the Society of Thoracic Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry were analyzed and compared with outcomes after native-valve TAVR using the same valve platform during the same study period. The primary endpoints were all-cause mortality, stroke, and readmission at 30 days and 1 year.

RESULTS

Among 439 redo-TAVR patients (mean age 78.9 ± 9.8 years, 63.1% women), procedural complication rates were low. Redo-TAVR reduced transvalvular gradients at 1 year, although gradients remained modestly higher than after native TAVR (11.3 ± 6.1 mm Hg vs 8.2 ± 4.6 mm Hg; P < 0.001). After adjustment, clinical outcomes were similar between redo-TAVR and native TAVR at 30 days (mortality adjusted HR: 0.66 [95% CI: 0.39-1.13; P = 0.129]; stroke adjusted HR: 0.95 [95% CI: 0.54-1.68; P = 0.853]; readmission adjusted HR: 0.88 [95% CI: 0.65-1.20; P = 0.422]) and 1-year (mortality adjusted HR: 0.91 [95% CI: 0.72-1.15; P = 0.441]; stroke adjusted HR: 0.91 [95% CI: 0.63-1.34; P = 0.644]; readmission adjusted HR: 0.92 [95% CI: 0.76-1.13; P = 0.439]). Improvements in functional status and quality of life were observed early after redo-TAVR and were sustained through 1 year. Findings were consistent across prespecified subgroups.

CONCLUSIONS

In a national registry, redo-TAVR with the Evolut platform was associated with low procedural complication rates and clinical outcomes comparable with those observed with native TAVR. These findings support redo-TAVR with Evolut as a feasible and effective treatment strategy in appropriately selected patients.

Для цитирования: Rogers Toby, Bapat Vinayak N, Chetcuti Stanley J, Dauerman Harold L, Forrest John K, Goel Sachin S, Grubb Kendra J, Htun Wah Wah, Puri Rishi, Reardon Michael J, Tang Gilbert H L, Vora Amit N, Yakubov Steven J, Eisenberg Ruth, Attizzani Guilherme F. Redo-Transcatheter Aortic Valve Replacement With Self-Expanding Valves: A U.S. Registry Analysis.. JACC. Cardiovascular interventions. 2026. DOI: 10.1016/j.jcin.2026.07.009.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.